Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
about
Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of actionClinical applicability of molecular biology: the case of the long QT syndrome.Long-QT syndrome: from genetics to managementMolecular and genetic basis of sudden cardiac deathHuman iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correctionRecent advances in genetic testing and counseling for inherited arrhythmiasThe role of the SCN5A-encoded channelopathy in irritable bowel syndrome and other gastrointestinal disorders2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of theRate dependency of delayed rectifier currents during the guinea-pig ventricular action potentialA novel and lethal de novo LQT-3 mutation in a newborn with distinct molecular pharmacology and therapeutic responseComparison of Gating Properties and Use-Dependent Block of Nav1.5 and Nav1.7 Channels by Anti-Arrhythmics Mexiletine and LidocaineA large family characterised by nocturnal sudden death.Cardiac pacing in the long QT syndrome: review of available data and practical recommendations.Regulation of the voltage-gated K+ channel KCNA10 by KCNA4B, a novel beta-subunit.Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.Inherited long QT syndromes: a paradigm for understanding arrhythmogenesis.Familial and acquired long qt syndrome and the cardiac rapid delayed rectifier potassium current.Long QT Syndromes.Ventricular tachycardia in structurally normal hearts.Ventricular tachycardia during general anesthesia in a patient with congenital long QT syndrome.Characterization of the cardiac sodium channel SCN5A mutation, N1325S, in single murine ventricular myocytes.Age- and genotype-specific triggers for life-threatening arrhythmia in the genotyped long QT syndrome.Mutation-specific risk in two genetic forms of type 3 long QT syndrome.Beta-blocker efficacy in high-risk patients with the congenital long-QT syndrome types 1 and 2: implications for patient managementPharmacological and non-pharmacological management of the congenital long QT syndrome: the rationaleSuccessful elimination of significant arrhythmia burden with flecainide in an adolescent with long QT syndrome type 3.Congenital long QT syndrome: A case reportGenotype-specific risk stratification and management of patients with long QT syndrome.Novel calmodulin mutations associated with congenital arrhythmia susceptibility.Congenital and drug-induced long-QT syndrome: an update.Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3.Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter StudyMolecular biology of the long QT syndrome: impact on management.Clinical management of patients with the long QT syndrome: drugs, devices, and gene-specific therapy.Management of patients with the hereditary long QT syndrome.The molecular and ionic specificity of antiarrhythmic drug actions.Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trialA case of long QT syndrome: challenges on a bumpy road.In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.Channel-specific therapy of cardiac arrhythmias in our time?
P2860
Q24671796-5F72C3F1-A85D-4447-AF06-9F816D45CE9CQ24792627-A8A86B37-FC47-4A09-9CCD-B265E1F5C3EFQ26823298-2DFE6DCF-7837-427E-BC60-71CC28C421E0Q26825973-C8316302-DF87-408A-8677-97997126E570Q27322725-47CB540E-D1D1-4C16-A5B0-755144ADAEEDQ28074154-FBD838EF-7675-4417-8133-FD9A1F2DE2FAQ28081627-BCEEB00D-8E38-4963-B56D-AF828F88DFA4Q28087002-0C2481B0-30D1-4572-911B-FB3CBE26AC31Q28345142-94F2F938-B39E-4AD2-AB2E-E0323938D9A1Q28471659-25A0524B-9EDE-41B7-A375-4ECE1DDEF75DQ28548133-77A88A21-4BB2-4188-A4BE-770F59965089Q30493789-31D3D2F2-AB2E-415A-8A0C-730C55785490Q30596756-74CFE77E-7891-438A-B833-073645033994Q31076444-E18C4126-F45A-4BF9-A411-F44346D38126Q31136281-E9E0E3C4-CE7C-4A18-9F14-2340C0BBB741Q33145216-AD1D1D22-E7B7-4293-908B-D0F6D866162BQ33145803-D423ADBA-073B-4143-9FCA-F07551B5F886Q33145925-A62E2785-E7A1-424F-9D85-5A5D0D8B5DD0Q33147996-64BB1D22-219B-43D1-B53B-EAA4E9E036C6Q33148770-BF7F67EB-EC22-4E11-8E1A-0FAF62ADAE4BQ33154501-1798FEFD-6121-4FD5-AF03-A507AD82CC91Q33156126-3DD31729-60A5-41A4-9F39-244B7E22A4D8Q33158299-AFFAAE32-65ED-4538-9EC8-B17ECF4DD83CQ33158481-25C5716B-EC41-4091-BA20-402CEF3DDBD0Q33159820-CD9A581E-D400-4902-A4C5-69F1F20588BBQ33160736-78951FFC-7775-4D8E-8BD5-782E955CE8D2Q33160884-D3B90A38-680E-491D-BAF4-211B8AFAA5F8Q33163507-6534855D-2A48-400F-B2F3-477957914170Q33164413-EAFE8145-06EC-47F5-920F-8693CA6522CBQ33165312-B35A918E-20BD-4F21-BAC5-8A5D5EB6D26DQ33166896-52D4DCEC-42CA-4D2C-8F98-F87C83F8AC49Q33167640-5F36083A-E77B-48D5-98F0-A870B5878B71Q33175314-40D39C25-CC5C-4B21-8569-F0C54A7BB39DQ33175315-E7BCCAF2-F209-475E-B535-93BB3F537331Q33175681-2F39E5E5-8C9F-4E02-B7B7-31E778C3B9E5Q33544546-1A072F3E-DFD0-4B89-B6DC-CF1FB159573CQ33647242-424188C6-ACB9-471E-8770-ECF67B797D40Q33761127-19723C42-187D-4CFE-A7C3-2AA766FF8E92Q33791988-22F5415E-2196-4547-B04A-EC20C16CA529Q33882443-B5C62838-3C9D-48FF-B397-A35335F867D6
P2860
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy.
description
1995 nî lūn-bûn
@nan
1995 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Long QT syndrome patients with ...... ons for gene-specific therapy.
@ast
Long QT syndrome patients with ...... ons for gene-specific therapy.
@en
type
label
Long QT syndrome patients with ...... ons for gene-specific therapy.
@ast
Long QT syndrome patients with ...... ons for gene-specific therapy.
@en
prefLabel
Long QT syndrome patients with ...... ons for gene-specific therapy.
@ast
Long QT syndrome patients with ...... ons for gene-specific therapy.
@en
P2093
P1433
P1476
Long QT syndrome patients with ...... ions for gene-specific therapy
@en
P2093
E H Locati
H Hammoude
J A Towbin
M T Keating
P J Schwartz
S G Priori
T J Colatsky
P304
P356
10.1161/01.CIR.92.12.3381
P407
P577
1995-12-01T00:00:00Z